Skip to main content
. 2024 Jan 18;13:1268584. doi: 10.3389/fonc.2023.1268584

Figure 3.

Figure 3

Cost-effectiveness acceptability curve for comparison among various treatment regimens. (A), ITT population, (B), PD-L1+ subgroup, (C), ITT population after toripalimab is included in medical insurance, (D), PD-L1+ subgroup after toripalimab is included in medical insurance; CE, cost-effectiveness.